Nymox Pharmaceutical Statistics
Total Valuation
Nymox Pharmaceutical has a market cap or net worth of 10.29 million. The enterprise value is 10.97 million.
| Market Cap | 10.29M |
| Enterprise Value | 10.97M |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Nymox Pharmaceutical has 93.54 million shares outstanding. The number of shares has increased by 2.58% in one year.
| Shares Outstanding | 93.54M |
| Shares Change (YoY) | +2.58% |
| Shares Change (QoQ) | -0.40% |
| Owned by Insiders (%) | 44.59% |
| Owned by Institutions (%) | 0.05% |
| Float | 51.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.24 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.70 |
Financial Position
The company has a current ratio of 0.16
| Current Ratio | 0.16 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.18 |
| Interest Coverage | -136.89 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -463.48% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -552,750 |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.69% in the last 52 weeks. The beta is 0.31, so Nymox Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | -67.69% |
| 50-Day Moving Average | 0.06 |
| 200-Day Moving Average | 0.28 |
| Relative Strength Index (RSI) | 50.60 |
| Average Volume (20 Days) | 8,114 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.82 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.35M |
| Pretax Income | -8.84M |
| Net Income | -8.84M |
| EBITDA | -8.34M |
| EBIT | -8.35M |
| Earnings Per Share (EPS) | -0.10 |
Balance Sheet
The company has 70,000 in cash and 750,000 in debt, giving a net cash position of -680,000 or -0.01 per share.
| Cash & Cash Equivalents | 70,000 |
| Total Debt | 750,000 |
| Net Cash | -680,000 |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -3.17M |
| Book Value Per Share | -0.03 |
| Working Capital | -3.18M |
Cash Flow
In the last 12 months, operating cash flow was -4.06 million and capital expenditures -3,000, giving a free cash flow of -4.06 million.
| Operating Cash Flow | -4.06M |
| Capital Expenditures | -3,000 |
| Free Cash Flow | -4.06M |
| FCF Per Share | -0.04 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nymox Pharmaceutical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.58% |
| Shareholder Yield | -2.58% |
| Earnings Yield | -87.69% |
| FCF Yield | -39.46% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |